33.22 -0.08 (-0.24%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 39.87 | 1-year : | 41.86 |
Resists | First : | 34.14 | Second : | 35.84 |
Pivot price | 33.7 ![]() |
|||
Supports | First : | 31.38 | Second : | 26.11 |
MAs | MA(5) : | 33.19 ![]() |
MA(20) : | 33.81 ![]() |
MA(100) : | 42.84 ![]() |
MA(250) : | 40.35 ![]() |
|
MACD | MACD : | -1 ![]() |
Signal : | -1.2 ![]() |
%K %D | K(14,3) : | 41.1 ![]() |
D(3) : | 32.3 ![]() |
RSI | RSI(14): 42.2 ![]() |
|||
52-week | High : | 62.58 | Low : | 26.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AGIO ] has closed above bottom band by 28.6%. Bollinger Bands are 81.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 34.72 - 34.9 | 34.9 - 35.06 |
Low: | 32.44 - 32.64 | 32.64 - 32.81 |
Close: | 32.89 - 33.23 | 33.23 - 33.52 |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Fri, 14 Feb 2025
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade) - Seeking Alpha
Fri, 14 Feb 2025
Rep. Gilbert Ray Cisneros, Jr. Buys Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock - MarketBeat
Fri, 14 Feb 2025
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues - Yahoo Finance
Fri, 14 Feb 2025
Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlight - GuruFocus.com
Thu, 13 Feb 2025
Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years - Benzinga
Thu, 13 Feb 2025
Agios Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | -157 (M) |
Shares Float | 0 (M) |
Held by Insiders | 5.703e+007 (%) |
Held by Institutions | 5.051e+007 (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | -2.6658e+008 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 11.65 |
Profit Margin | 2 % |
Operating Margin | 51.3 % |
Return on Assets (ttm) | -1 % |
Return on Equity (ttm) | 146.9 % |
Qtrly Rev. Growth | 53.6 % |
Gross Profit (p.s.) | 37.86 |
Sales Per Share | -59.9 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -4.0129e+008 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 2.84 |
Price to Sales | -0.56 |
Price to Cash Flow | 0 |
Dividend | 5.35e+006 |
Forward Dividend | 5.12e+006 |
Dividend Yield | 16104800% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |